Quarterly report pursuant to Section 13 or 15(d)

Accrued expenses and other current liabilities

v3.8.0.1
Accrued expenses and other current liabilities
 9 Months Ended
Sep. 30, 2017
Accrued expenses and other current liabilities  
Accrued expenses and other current liabilities

 

Note 8 — Accrued expenses and other current liabilities

 

Accrued expenses and other current liabilities consisted of the following (in thousands):

 

 

 

September 30, 
2017

 

December 31,
2016

 

Clinical & Development Accruals

 

$
7,540

 

$
4,938

 

Accrued employee expenses

 
5,351

 
4,539

 

Accrued capital expenditure

 
709

 
3,954

 

VAT

 
6,067

 
2,014

 

Accrued expenses

 
3,486

 
1,003

 

Other

 
338

 
1,080

 

 

 

 

 

 

 

 

 

$
23,491

 

$
17,528

 

 

 

 

 

 

 

 

 

 

The Company typically has a receivable for VAT.  At September 30, 2017 and December 31, 2016, there was a VAT payable due to VAT arising on the milestone payments invoiced to GSK in the previous quarter.